Home Cart 0 Sign in  

[ CAS No. 135097-68-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 135097-68-6
Chemical Structure| 135097-68-6
Structure of 135097-68-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 135097-68-6 ]

Related Doc. of [ 135097-68-6 ]

Alternatived Products of [ 135097-68-6 ]

Product Details of [ 135097-68-6 ]

CAS No. :135097-68-6 MDL No. :MFCD14635672
Formula : C17H25NO4 Boiling Point : -
Linear Structure Formula :- InChI Key :-
M.W : 307.39 Pubchem ID :-
Synonyms :

Safety of [ 135097-68-6 ]

Signal Word: Class:
Precautionary Statements: UN#:
Hazard Statements: Packing Group:

Application In Synthesis of [ 135097-68-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 135097-68-6 ]
  • Downstream synthetic route of [ 135097-68-6 ]

[ 135097-68-6 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 135097-68-6 ]
  • [ 135065-71-3 ]
YieldReaction ConditionsOperation in experiment
100% for 16 h; Intermediate 111 (19.8 g, 64.4 mmol) was stirred under an atmosphere of hydrogenin the presence of 10percent Pd/C (1.98 g, 1.86 mmol) for 16 h. The catalyst wasremoved by vacuum filtration and the filtrate concentrated at reduced pressure to give 13.98 g (100percent yield) of the title compound as a colourless viscous oil, which crystallised on standing.1H NMR (250 MHz, chloroform-d): 6 [ppm] 3.98 - 3.75 (m, 3H), 3.73 - 3.41 (m, 4H),3.03- 2.83 (m, 1H), 2.82-2.65 (m, 1H), 2.12 (t, J = 5.9 Hz, 1H), 1.45 (5, 9H).
99% With hydrogen In ethanol at 20℃; To a solution of (R)-tert-buty{ 2-(benzyloxymethyl)morpholine-4-carboxylate (8.33 g, 27.1 mmol) in EtOH was added Pd-C (wet, 3.6 g), and the resulting mixture was stirred at rt under a H2 balloon overnight. After filtration, the solvent was removed under vacuum, and the residue was purified by flash column chromatography to give (R)-tert-buty\\ 2-(hydroxymethyl)morpholine-4-carboxylate (5.84 g, 99 percent) as a clear oil. 1H NMR (400MHz, CDCl3): 3.88 (d, 2 H), 3.82 (br, 1 <n="115"/>H), 3.64 (d, 1 H), 3.56 (m, 3 H), 2.94 (m, 1 H), 2.76 (m, 1 H), 1.90 (br, 1 H), 1.44 (s, 9 H); MS m/z 218 (M+H+).
99% With hydrogen In ethanol Step 3.
(R)-tert-Butyl 2-(hydroxymethyl)morpholine-4-carboxylate
To a solution of (R)-tert-butyl 2-(benzyloxymethyl)morpholine-4-carboxylate (8.33 g, 27.1 mmol) in EtOH was added Pd-C (wet, 3.6 g), and the resulting mixture was stirred at rt under a H2 atmosphere overnight.
After filtration, the solvent was removed under vacuum and the residue was purified by flash column chromatography to give (R)-tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (5.84 g, 99percent) as a clear oil. 1H NMR (400 MHz, CDCl3): δ=3.88 (d, 2H), 3.82 (br, 1H), 3.64 (d, 1H), 3.56 (m, 3H), 2.94 (m, 1H), 2.76 (m, 1H), 1.90 (br, 1H), 1.44 (s, 9H); MS m/z 218 (M+H+).
99% With hydrogen In 20 C To a solution of (K)-tert-butyl 2-(benzyloxymethyl)rnorpholine-4-carboxylate (8.33 g, 27.1 mmol) in EtOH was added Pd-C (wet, 3.6 g), and the resulting mixture was stirred at rt under a H2 balloon overnight. After filtration, the solvent was removed under vacuum, and the residue was purified by flash column chromatography to give (R)-tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (5.84 g, 99 percent) as a clear oil. 1H NMR (400MHz, CDCl3): 3.88 (d, 2 H), 3.82 (br, 1 H), 3.64 (d, 1 H), 3.56 (m, 3 H), 2.94 (m, 1 H), 2.76 (m, 1 H), 1.90 (br, 1 H), 1.44 (s, 9 H); MS m/z 218 (M+H*).
99% With hydrogen In ethanol at 20℃; To a solution of (R)-tert-butyl 2-(benzyloxymethyl)morpholine-4-carboxylate (8.33 g, 27.1 mmol) in EtOH was added Pd-C (wet, 3.6 g), and the resulting mixture was stirred at rt under a H2 balloon overnight. After filtration, the solvent was removed under vacuum, and the residue was purified by flash column chromatography to give (R)-tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (5.84 g, 99percent) as a clear oil. 1H NMR (400 MHz, CDCl3) δ ppm 3.88 (d, 2H), 3.82 (br, 1H), 3.64 (d, 1H), 3.56 (m, 3H), 2.94 (m, 1H), 2.76 (m, 1H), 1.90 (br, 1H), 1.44 (s, 9H); MS m/z 218 (M+H+).
99% With hydrogen In ethanol at 20℃; Step 3. (R)-tert-Buty\\ 2-(hydroxymethyl)morpholine-4-carboxylate: To a solution of (R)-tert-buty\\ 2-(benzyloxymethyl)morpholine-4-carboxylate (8.33 g, 27.1 mmol) in EtOH was added Pd-C (wet, 3.6 g), and the resulting mixture was stirred at rt under a H2 balloon overnight. After filtration, the solvent was removed under vacuum, and the residue was purified by flash column chromatography to give (R)- tert-butyi 2-(hydroxymethyl)morpholine-4-carboxylate (5.84 g, 99 percent) as a clear oil. 1H NMR (400MHz, CDCl3): 3.88 (d, 2 H), 3.82 (br, 1 H), 3.64 (d, 1 H), 3.56 (m, 3 H), 2.94 (m, 1 H), 2.76 (m, 1 H), 1.90 (br, 1 H), 1.44 (s, 9 H); MS m/z 218 (M+H+).
99% With hydrogen In methanol at 20℃; To a solution of (K)-lert-buy\\ 2-(benzyloxymethyl)morpholine-4- carboxylate (8.33 g, 27.1 mmol) in EtOH was added Pd-C (wet, 3.6 g), and the resulting mixture was stirred at rt under a H2 balloon overnight. After filtration, the solvent was removed under vacuum and the residue was purified by flash column chromatography to give (R)-tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (5.84 g, 99 percent) as a clear oil. 1H NMR (400MHz, CDCl3): 3.88 (d, 2 H)5 3.82 (br, 1 H)3 3.64 (d, 1 H)3 3.56 (m3 3 H), 2.94 (m, 1 H), 2.76 (m, 1 H), 1.90 (br, 1 H), 1.44 (s3 9 H); MS m/z 218 (M+H+).
99% With hydrogen In ethanol at 20℃; Step 3. (R)-tert-Butyl 2-(hydroxymethyl)morpholine-4-carboxylate. To a solution of (R)-ter/-butyl 2-(benzyloxymethyl)morpholine-4- carboxylate (8.33 g, 27.1 mmol) in EtOH was added Pd-C (wet, 3.6 g), and the resulting mixture was stirred at rt under a H2 balloon overnight. After filtration, the solvent was removed under vacuum and the residue was purified by flash column chromatography to give (R)-.erf-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (5.84 g, 99 percent) as a clear oil. 1H NMR (400MHz, CDCl3): 3.88 (d, 2 H), 3.82 (br, 1 H), 3.64 (d, 1 H), 3.56 (m, 3 H), 2.94 (m, 1 H), 2.76 (m, 1 H), 1.90 (br, 1 H), 1.44 (s, 9 H); MS m/z 218 (M+H+).
92% With hydrogen In ethanol for 16 h; Step b) 2R-Hydroxymethyl-morpholine-4-carboxylic acid tert-butyl ester The oil (1.80 g) was dissolved in 50 ml ethanol and 100 mg palladium on carbon (10percent) was added. The mixture was hydrogenated at 1 atm H2- EPO <DP n="30"/>pressure for 16 h, filtered through silica/alumina (5 cm and 0.5 cm, respectively) and concentrated in vacuo yielding 1.18 g (92percent) 2R- hydroxymethyl-morpholine-4-carboxylic acid tert-butyl ester as a white crystalline solid.
92% With hydrogen In ethanol at 20℃; for 16 h; The oil (1.80 g) was dissolved in 50 ml ethanol and 100 mg palladium on carbon (10percent) was added. The mixture was hydrogenated at 1 atm H2-pressure for 16 h, filtered through silica/alumina (5 cm and 0.5 cm, respectively) and concentrated in vacuo yielding 1.18 g (92percent) 2R-hydroxymethyl-morpholine-4-carboxylic acid tert-butyl ester as a white crystalline solid.
59% With hydrogen In ethanol at 70℃; (R)-2-Benzyloxymethyl-morpholine-4-carboxylic acid tert-butyl ester 1c (1.02 g, 3.32 mmol) and 0.45 g of palladium on activated carbon were added to a reaction flask. The reaction flask was purged with hydrogen for three times. 10 mL of ethanol was added under hydrogen atmosphere. The reaction mixture was stirred overnight at 70°C and monitored by thin layer chromatography until the disappearance of the starting materials. The resulting mixture was purified by silica gel column chromatography to obtain the title compound (R)-2-hydroxymethyl-morpholine-4-carboxylate acid tert-butyl ester 1d (0.428 g, yield 59percent) as a colorless oil. MS m/z (ESI): 240.3 [M+1]. 1H NMR (CDCl3, 400 MHz) δ 3.92-3.88 (m, 3H), 3.7-3.64 (m, 1H), 3.60-3.48 (m, 3H), 2.936 (m, 1H), 2.75 (m, 1H), 2.06 (m, 1H), 1.46 (s, 9H).
59% With hydrogen In ethanol at 70℃; (R)-2-Benzyloxymethyl-morpholine-4-carboxylic acid tert-butyl ester 1c (1.02 g, 3.32 mmol) and 0.45 g of palladium on activated carbon were added to a reaction flask. The reaction flask was purged with hydrogen for three times. 10 mL of ethanol was added under hydrogen atmosphere. The reaction mixture was stirred overnight at 70° C. and monitored by thin layer chromatography until the disappearance of the starting materials. The resulting mixture was purified by silica gel column chromatography to obtain the title compound (R)-2-hydroxymethyl-morpholine-4-carboxylate acid tert-butyl ester 1d (0.428 g, yield 59percent) as a colorless oil.MS m/z (ESI): 240.3 [M+1].1H NMR (CDCl3, 400 MHz) δ 3.92-3.88 (m, 3H), 3.7-3.64 (m, 1H), 3.60-3.48 (m, 3H), 2.936 (m, 1H), 2.75 (m, 1H), 2.06 (m, 1H), 1.46 (s, 9H).

Reference: [1] Heterocycles, 1993, vol. 35, # 1, p. 105 - 109
[2] Patent: WO2016/91776, 2016, A1, . Location in patent: Page/Page column 290
[3] Patent: WO2008/124575, 2008, A1, . Location in patent: Page/Page column 112; 113-114
[4] Patent: US2010/184805, 2010, A1, . Location in patent: Page/Page column 30-31
[5] Patent: WO2007/70201, 2007, A1, . Location in patent: Page/Page column 176
[6] Patent: US2010/317697, 2010, A1, . Location in patent: Page/Page column 51
[7] Patent: WO2008/124582, 2008, A1, . Location in patent: Page/Page column 93-97
[8] Patent: WO2007/117560, 2007, A2, . Location in patent: Page/Page column 182; 189
[9] Patent: WO2007/117557, 2007, A2, . Location in patent: Page/Page column 79
[10] Patent: WO2007/6715, 2007, A1, . Location in patent: Page/Page column 28-29
[11] Patent: WO2007/6714, 2007, A1, . Location in patent: Page/Page column 120
[12] Patent: EP2189451, 2010, A1, . Location in patent: Page/Page column 10
[13] Patent: US2010/210640, 2010, A1, . Location in patent: Page/Page column 9
[14] Patent: EP411912, 1991, A2,
[15] Patent: WO2007/11292, 2007, A1, . Location in patent: Page/Page column 29-30
[16] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 16, p. 4836 - 4843
[17] European Journal of Medicinal Chemistry, 2017, vol. 127, p. 757 - 770
  • 2
  • [ 135097-68-6 ]
  • [ 884512-77-0 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 16, p. 4836 - 4843
[2] Patent: WO2007/117560, 2007, A2,
[3] Patent: WO2007/117557, 2007, A2,
[4] Patent: WO2008/124582, 2008, A1,
Same Skeleton Products
Historical Records